PHA665752 is a selective inhibitor of the c-Met kinase, a receptor tyrosine kinase implicated in tumor growth, invasion, and metastasis. It is primarily used in cancer research to study signaling pathways associated with c-Met activation. The compound demonstrates potent anti-tumor activity in preclinical models, particularly in cancers driven by c-Met dysregulation, such as certain lung, liver, and gastric cancers. It has been utilized in studies to evaluate the effects of c-Met inhibition on cell proliferation, apoptosis, and tumor angiogenesis. Due to its specificity, PHA665752 serves as a valuable tool for validating c-Met as a therapeutic target and for developing combination therapies with other anticancer agents.